Co-Diagnostics CEO to Discuss Progress and Forecasts in a Lytham Partners’ Virtual Investors Conference Presentation on Tuesday, December 4, 2018 at 4:00 pm ET
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company
with a unique, patented platform for the development of molecular
diagnostic tests, announced today that it will discuss the Company’s
recent progress and upcoming sales expectations on Tuesday, December 4,
2018 at 4:00 pm ET (3:00 pm CT) in a Lytham Partners’ Virtual Investors
Conference Presentation. The presentation will be available online with
interested parties able to participate by following the webcast links
below at the time of the presentation.
The presentation will be conducted by Mr. Dwight Egan, Chairman and
Chief Executive Officer of the Company, and is expected to consist of a
Company progress update and review of milestones reached in 2018,
followed by the Company’s expectations for near-term sales and questions
from the audience. The event will be moderated by Joe Diaz, managing
partner at Lytham Partners.
| Event: | Co-Diagnostics, Inc. Virtual Presentation and Fireside Chat | ||
| Date: |
Tuesday, December 4, 2018 |
||
| Time: | 4 pm ET (3 pm CT; 2 pm MT; 1 pm PT) | ||
|
Webcast: |
By accessing the link here |
A replay of the presentation will be available on demand following the
conclusion of the live event.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company with a patented diagnostic testing technology and development
platform that intends to manufacture and sell reagents used for
diagnostic tests that function via the detection and/or analysis of
nucleic acid molecules (DNA or RNA). The Company also uses its
proprietary technology to design specific tests to locate genetic
markers for use in industries other than infectious disease and license
the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
“believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will”
and similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future
facts and conditions. Forward-looking statements in this release
include statements regarding the (i) use of funding proceeds, (ii)
expansion of product distribution, (iii) acceleration of initiatives in
liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in the
near-term, (vii) flexibility in managing the Company’s balance sheet,
(viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements are
subject to inherent uncertainties, risks and changes in circumstances.
Actual results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this press
release are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this press
release, except as may be required by applicable securities laws.
Contacts
Company Contact:
Andrew Benson
Co-Diagnostics Investor
Relations
801-438-1036
investors@codiagnostics.com
Investor Contact:
Joe Diaz, Robert Blum and Joe Dorame
Lytham
Partners, LLC
602-889-9700
codx@lythampartners.com
